



Cite this: *RSC Adv.*, 2018, 8, 35998

# One-step preparation of novel 1-(*N*-indolyl)-1,3-butadienes by base-catalysed isomerization of alkynes as an access to 5-(*N*-indolyl)-naphthoquinones†

C. M. Pis Diez, <sup>ab</sup> J. F. Fernandez, <sup>ab</sup> G. Di Venosa, <sup>c</sup> A. Casas, <sup>c</sup> R. Pis Diez <sup>\*d</sup> and J. A. Palermo <sup>\*ab</sup>

A series of novel 1-(*N*-indolyl)-1,3-butadienes, as (1 : 1) mixtures of the (*E*) and (*Z*) dienes, was prepared in one step by base-catalysed isomerization of *N*-alkylindoles with a terminal butyne chain. The reaction conditions are mild, and in all cases the yields were very high (>90%). The (*E*) and (*Z*) dienes were separable by preparative TLC and could be fully characterized. This isomerization proceeded readily in the case of a butynyl chain, but didn't take place with a pentynyl chain. A mechanism was proposed for this reaction, based on previous studies on the isomerization of alkynes in basic media, and a key intermediate that supports the proposed mechanism could be isolated and fully characterized. A theoretical study of the proposed mechanism was performed by computational methods and the results validated the proposal. The reactivity of the synthesized dienes was studied in Diels–Alder reactions with *p*-benzoquinone, to obtain a small library of new 5-(*N*-indolyl)-1,4-naphthoquinones. The lack of reactivity in the case of the (*Z*) isomers was explained by calculation of the rotational curves of the central bond of the (*Z*) and (*E*) dienes. Finally, the cytotoxicity of the new 5-(*N*-indolyl)-1,4-naphthoquinones was tested against a panel of three cell lines.

Received 17th June 2018  
 Accepted 15th October 2018

DOI: 10.1039/c8ra05208e

rsc.li/rsc-advances

## Introduction

Substituted 1,3-butadienes are versatile building blocks in organic synthesis, and the preparation of these compounds is still an active field in organic chemistry.<sup>1</sup> However, to date there have been no reports on the preparation of 1-(*N*-indolyl)-1,3-butadienes. During the course of a project of structural diversification of indole alkaloids by means of click reactions, it was necessary to prepare *N*-substituted indoles with alkyl chains bearing terminal triple bonds. The typical *N*-substitution reaction in DMSO and base (with the use of NaOH instead of NaH) with 5-Cl-1-pentyne as alkylating agent proceeded smoothly. However, when the reaction was attempted using 4-Br-1-butyne, the outcome was different, and a (1 : 1) mixture of (*Z*) and (*E*) 1-*N*-indolyl-1,3-butadienes was

obtained instead (Fig. 1). Taking into account that the indole moiety is a frequent motif in many natural products and bioactive drugs,<sup>2</sup> the use of this reaction was explored for the preparation and characterization of a series of dienes with different substituted indoles or carbazole at C-1 (1–7a,b Fig. 2). Furthermore, the reactivity of these dienes in Diels Alder reactions was explored using benzoquinone as dienophile to obtain a family of new cytotoxic 5-*N*-indolyl-1,4-naphthoquinones.<sup>3</sup>

## Results and discussion

During the course of the reaction of indole and 4-Br-1-butyne, the formation of an initial product was detectable by TLC at




Fig. 1 *N*-alkylation of indole with terminal C-4 and C-5 haloalkynes.

<sup>a</sup>Universidad de Buenos Aires, Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Ciudad Universitaria, Pabellón 2 – (1428), Buenos Aires, Argentina. E-mail: palermo@qo.fcen.uba.ar

<sup>b</sup>CONICET-Universidad de Buenos Aires, Unidad de Microanálisis y Métodos Físicos en Química Orgánica (UMYFOR), Buenos Aires, Argentina

<sup>c</sup>Centro de Investigaciones sobre Porfirinas y Porfirias (CIPYP) CONICET and Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Córdoba 2351, 1<sup>er</sup> subsuelo, Ciudad de Buenos Aires, 1120AAF Buenos Aires, Argentina

<sup>d</sup>CEQUINOR (CONICET-CCT-La Plata, UNLP), Bvd 120 N1465, 1900 La Plata, Argentina

† Electronic supplementary information (ESI) available: NMR spectra, energy curves for C-5 alkyne. See DOI: 10.1039/c8ra05208e






Fig. 2 Synthesis of 1-(*N*-indolyl) and 1-(*N*-carbazolyl)-1,3-butadienes.

early stages, before complete conversion of the starting compound. This product was isolated and identified as 1-*N*-(2-butyne)-indole (**12**), an isomer of the expected product (**8**). However, when the reaction was taken to completion, compound **12** was replaced by a less polar product. Analysis of this product by  $^1\text{H}$  NMR showed that it was more complex than expected, with no observable signals of protons bound to  $\text{sp}^3$  carbons. Instead, two dienic systems were clearly observable, and a complete structural elucidation by 2D NMR proved that these dienes were bound to different indole nitrogens. Especially notable were the differences in the geometry of the 1,2 double bond of the dienes. In one case a  $J = 17$  Hz clearly indicated an *E* geometry, while in the other case a coupling constant of 10 Hz was indicative of a *Z* configuration. In this way the product was identified as a (1 : 1) mixture of (*Z*) and (*E*) 1-(*N*-indolyl)-1,3-butadiene (**1a,b**). Surprisingly, these dienes had never been synthesized. There are previous syntheses of a 1-(*N*-carbazolyl)-1,3-butadiene and 1-(*N*-phtalimido)-1,3-butadiene, albeit by a completely different methodology, based on cross-coupling reactions of *N*-vinyl derivatives.<sup>4</sup> Since the obtained yield in the present work was higher than 90%, a family of these compounds was prepared in this way from different substituted indoles, and also from carbazole. The reaction was not feasible using  $\text{K}_2\text{CO}_3$  as base, either in acetone or DMSO, while the use of NaH or stronger bases would form alkyne salts. The presence of a strong electron-attracting substituent such as a nitro group (as in 3-nitrocarbazole) produces the failure of the *N*-alkylation step. In all the cases where the isomerization took place, the (*Z*) and (*E*) dienes were separable by preparative TLC, and completely characterized by NMR and MS.

The complete isomerization of the alkynes to form these butadienes were unexpected results, although it is known that the reaction between a terminal alkyne and a catalytic amount of base gives rise to a mixture of isomers. This process was described by Favorskii as early as 1887, and its mechanism has been revised several times.<sup>5</sup> In the case of hydrocarbon-type

alkynes, which require strong bases and high temperatures for isomerization, the main products are generally disubstituted acetylenes and allenes. Quite surprisingly, conjugated dienes, which would be the thermodynamically favored species, are only formed under forcing temperature conditions.<sup>6</sup> In the case of acetylenic nitrogen-substituted compounds, the required conditions for the isomerization are generally milder, and the prevailing product depends on the electronic nature of the nitrogen atom. In a study of the behaviour of different *N*-2-propynylamines under basic catalysed isomerization conditions, it was observed that a basic nitrogen atom as in *N,N*-dialkylamino substituents, produced the central, isomerized alkyne almost exclusively. However, with several heterocyclic substituents (1-*N*-pyrrolyl, 1-*N*-imidazolyl, 1-*N*-pyrazolyl) the main product was the allenic isomer. In the case of a *N*-carbazolyl group, the terminal alkyne was 100% isomerized to the corresponding allene.<sup>7</sup> However, no similar studies were carried out with *N*-substituted butynes, so there are no reports on the influence of the nitrogen atom on the isomerization of a C-4 alkyne to a conjugated diene.

In the present work, the isomerization proceeded under mild conditions (70 °C, NaOH in DMSO), with nearly quantitative yields of the dienes. In the case of the butyne chain, the isomerization is so favourable that the initial *N*-alkylation product without isomerization of the triple bond (**8**), was only detected as a trace component of the crude reaction mixture, and only when the reaction was stopped at an early stage. This behaviour was not observed when 5-Cl-1-pentyne was used as alkylating agent. In this case, the reaction proceeded as a normal *N*-alkylation without any isomerization of the triple bond under the same conditions and reaction times. It is well known that alkyne-diene isomerizations in basic media usually take place *via* a previous isomerization to a more substituted alkyne, which in turn takes place *via* allenic intermediates.<sup>8</sup> Although no allenic intermediates could be isolated from the crude mixture in this work, the finding of the isomerized central alkyne supports this proposal. A possible mechanism for this reaction is shown in Fig. 3. This mechanism is inspired in the accepted route for alkyne isomerizations in basic media, which occur by a series of equilibria that involve resonance-stabilized carbanions.<sup>9</sup> The initial *N*-substitution product **8**, forms in basic medium a resonance-stabilized propargyl carbanion (**9**). Allenic carbanions are particularly stable, and subsequent protonation gives the allene **10**. A similar allene-alkyne isomerization *via* carbanion **11** originates the disubstituted alkyne **12**, which could be isolated and fully characterized. This isomerization is kinetically favoured, and so the disubstituted alkyne is the first product observed in this reaction. The loss of a proton " $\alpha$ " to the allene group in compound **10**, would generate a carbanion (**13**), which in turn could lead to the diene formation. In previous studies such as in the case of unsubstituted C-5 alkynes, the formation of this anion was extremely slow and the conjugated diene was generally not observed. This was attributed to a lack of acidity of the " $\alpha$ " proton due to an inefficient resonance stabilization by the allene group. The presence of an indole moiety helps to stabilize the anion at the






Fig. 3 Mechanism for the alkyne-diene isomerization of compound 8.

" $\alpha$ " position of the allene, and so the formation of the corresponding anion and subsequent isomerization gives rise to the dienes **1a,b** as the final, thermodynamically stable products, albeit at a slower rate.

In order to validate the proposed mechanism, computational calculations were performed, starting from the initial non-isomerized alkyne **8**, with the use of the ORCA package.<sup>19</sup> These calculations were done for both the C-4 and the C-5 alkyne chain. First, the conformational space of the different compounds involved in the proposed mechanism was explored. Several starting structures were generated by selected modifications of dihedral angles of the side chain. The resulting starting geometries were optimized using the hybrid GGA exchange-correlation functional M06-2X,<sup>11</sup> with the Def2-TZVP basis set for all atoms.<sup>12</sup> To alleviate the computational cost, the resolution of the identity in its RIJCOSX version was used,<sup>13</sup> together with the corresponding basis functions for the calculation of the Coulomb and the exchange-correlation terms.<sup>14</sup> After optimization, the Hessian matrix of the energy with respect to the nuclear coordinates was constructed and diagonalized, and its eigenvalues were used to verify whether the geometries are local minima or saddle points on the potential energy surface of the molecules. Only the lowest-energy conformer of every species involved in the mechanism was used for the calculation of reaction or barrier energies. Solvent effects (DMSO) were considered implicitly through the Conductor-like Screening Model for geometry optimizations.<sup>15</sup>

Geometric parameters (bond lengths and dihedral angles) were calculated for the lowest-energy conformations of all the molecules involved in the proposed mechanism for the reaction of indole with the C-4 alkyne. It is interesting to note that in the final diene, the bond lengths of the N-C1', C7a-N and C2-N bonds are almost identical (1.383, 1.382 and 1.385 angstroms respectively). This means that the N-C1' bond has a marked double bond character.

Fig. 4 shows the  $\Delta G$ s of the different species for the C-4 chain, and it is evident the large energy drop to the final dienes, which makes this last step almost irreversible under

thermodynamic conditions. In this scheme, the final intermediate is a dienic carbanion (**13**), which adds a proton to give the final dienes. The small energy differences (0.4 kcal mol<sup>-1</sup>) between these final anions **13**, as well as of the corresponding transition states (0.7 kcal mol<sup>-1</sup>) which lead to the final (*E*) or (*Z*) butadienes, determine the observed (1 : 1) ratio of these compounds.

When the energy values are compared for the C-4 and C-5 chains (see ESI<sup>†</sup>) of the central disubstituted alkynes, which are the kinetically favoured products, it is evident that they are approximately equally stable. As for the final dienes, the final energy drop is also considerable. However, there are marked energy differences when carbanions **9** and **13** are compared. In the case of the butyne chain, carbanion **9** lies 1.85 kcal mol<sup>-1</sup> higher than the terminal alkyne **8**, with an energy barrier of 10.22 kcal mol<sup>-1</sup>. On the other hand, in the case of the pentyne chain, the energy difference between the terminal alkyne **8** and carbanion **9** is 6.86 kcal mol<sup>-1</sup>, while the energy barrier is in this case of 14.47 kcal mol<sup>-1</sup>. These values indicate that the anion **9** from the pentyne chain is less stabilized than the corresponding anion from the butyne chain, thus preventing the initial




Fig. 4 Calculated  $\Delta G$  for the route to the C-4 dienes.






Fig. 5 Diels Alder reaction between the *E* diene and *p*-benzoquinone.

isomerization under the mild conditions of this study. This stabilization of the C-4 anion **9** is probably caused by an inductive effect of the polarizable indole moiety.

This is in accordance with previous results obtained with an *N*-substituted indole bearing a C-3 alkyne. In this case, the isomerization occurred readily under very similar conditions to those of the present study, and gave rise to a mixture of both alkynes and the corresponding allene.<sup>6</sup> However, with this substrate, the reaction ended up in a mixture of isomers since it was not possible to reach the final diene, which is the irreversible step in the case of the butyne chain.

The possible use of the new dienes in Diels–Alder reactions was explored, using *p*-benzoquinone as dienophile (Fig. 5). Since the final product of this reaction under oxidizing conditions would be a substituted 1,4-naphthoquinone, namely a 5-(*N*-indolyl)-1,4-naphthoquinone, there was no need of a previous separation of the diene mixture. However, under all the different assayed conditions, the yields of substituted naphthoquinones were lower than 50%, and the conversion of the dienes was not complete. The recovered unreacted diene was in all cases the (*Z*) isomer, which accounts for the low yields of the reaction. This reaction was also attempted with the purified (*Z*) diene with no success, and, under forcing conditions, the compound decomposed readily.

It is known that (*Z*) isomers of 1-substituted 1,3-butadienes are much less reactive, or even totally unreactive in Diels Alder reactions compared to the (*E*) isomers. In (*Z*) dienes, the steric interaction between the substituent at C-1 and H-4 of the diene while adopting the *s-cis* configuration, produces a deviation from coplanarity of the diene system, a key requirement for the DA reaction, by rotation of the C2–C3 bond of the diene.<sup>16</sup> In the case of a methyl group at C-1, this deviation is small, but as the volume of the substituent increases, this interaction prevents coplanarity almost completely and makes the DA reaction extremely sluggish under thermal conditions. However, there are some recent examples of successful DA reactions of (*Z*) dienes using Lewis acid catalysis.<sup>17</sup> Unfortunately, in the present case, the use of  $\text{BF}_3 \cdot \text{O}(\text{Et})_2$  and other Lewis acids was unsuccessful.

The rotational energy curves of the central bond of the diene to go from the *s-trans* to the *s-cis* configuration, were calculated for the (*Z*) and (*E*) isomers of 1-(*N*-indolyl)-1,3 butadiene (Fig. 6). In the case of (*E*)-butadiene, the calculated skew angle was  $25.4^\circ$  at the lowest energy conformation for the *s-cis* conformation. The energy barrier between this minimum and the coplanar




Fig. 6 Calculated rotational energy curves for the central bond of the *E* (top) and *Z* (bottom) dienes.

conformation is just  $0.56 \text{ kcal mol}^{-1}$ . On the other hand, in the case of the (*Z*)-butadiene, the calculated skew angle was  $-56.5^\circ$ , and the access to the coplanar *s-cis* diene from the lowest energy conformation had an energy penalization of  $5.59 \text{ kcal mol}^{-1}$ . This gives a total energy difference for the planar *s-trans* – planar *s-cis* configurations of  $10.17 \text{ kcal mol}^{-1}$  for the (*Z*) isomer and of  $4.39 \text{ kcal mol}^{-1}$  for the (*E*) isomer, which explains the difference in reactivity of both compounds in thermal Diels–Alder reactions. A series of new 5-(*N*-indolyl)-1,4-naphthoquinones was synthesized from benzophenone and some of the new dienes (Fig. 7). Several natural and synthetic naphthoquinones have shown interesting pharmacological activities,<sup>18</sup> and, for this reason, the cytotoxicity of the synthesized compounds was evaluated against a small panel of cell lines (Table 1).

These results show that the new naphthoquinones are strongly cytotoxic, and, although additional tests should be performed against a wider panel of cell lines, these preliminary results may indicate a tendency to be generally toxic. However, naphthoquinones are interesting scaffolds for further derivatization, and it is possible that additional synthetic modifications may modulate the cytotoxicity of these new derivatives.








Fig. 7 Diels–Alder reaction products of compounds 1a–5a and 7a with *p*-benzoquinone.

Table 1 Cytotoxicity evaluation of compound 1c–5c and 7c

Comp.	IC50 (μM)		
	LM2	HaCat	K562
1c	7.15	4.02	5.91
2c	18.33	4.13	6.80
3c	7.54	4.24	3.96
4c	4.78	7.12	8.23
5c	3.31	3.22	2.34
7c	3.51	3.72	6.23

## Conclusions

In this work, a base-catalysed isomerization of *N*-alkylated indoles with a terminal butyne chain produced a series of 1-(*N*-indolyl)-1,3-butadienes, as (1 : 1) mixtures of chromatographically separable (*E*) and (*Z*) dienes. The same methodology was applicable to other heterocycles having an acidic *N*-bound proton, such as carbazole.

There are previous examples of *N*-alkylations with 4-bromo-1-butyne or the corresponding triflate, of 2-bromoindoles, cytosines, and imidazole and pyridine moieties in more complex molecules.<sup>19–21</sup> Interestingly, all these *N*-alkylations were performed using  $K_2CO_3$  as base either in acetone or in DMF, and in all cases the alkyne isomerization was not observed. The lack of isomerization was probably due to the weaker basicity of  $K_2CO_3$ , which was unable to form anion **9** and start the chain of isomerization equilibria. With the heterocyclic substrates used in the present work, *N*-alkylation did not take place with the use of  $K_2CO_3$  as base. The lack of reactivity of 3-nitrocarbazole towards *N*-alkylation with 4-bromo-1-butyne in NaOH/DMSO is also remarkable, since the formation of the anion was evidenced by a color change. This reaction was effective (although at a slow rate) with saturated alkyl halides

such as *n*-butylbromide. The presence of a strong electron-attracting substituent probably reduces the nucleophilicity of the anion of 3-nitrocarbazole, slowing the rate of the *N*-alkylation up to a point where an elimination reaction on the haloalkyne (to give a conjugated product) competes successfully.

Compared to the previous synthesis of 1-(*N*-indolyl)-carbazole in ref. 4, the present methodology is simpler, and does not require the use of expensive organometallic catalysts or inert atmosphere. Besides, this is a one-step process, a shorter route than the sequence of 2 or 3 steps in ref. 4. However, with the use of organometallic chemistry, the configuration of the diene can be controlled as almost exclusively (*E*), while in this work a (1 : 1) mixture of (*Z*) and (*E*) isomers are obtained, which requires a chromatographic separation to recover the pure dienes. Anyway, the present work has the advantage of simplicity, very high yields, and the possibility to prepare simultaneously both stereoisomers in one step. A possible mechanism was proposed for the alkyne-diene isomerization, and computational studies were performed to validate this proposal. A key intermediate for this mechanism, the central alkyne, could be isolated and fully characterized.

The obtained butadienes were used in Diels–Alder reactions to obtain a family of new cytotoxic 5-(*N*-indolyl)-1,4-naphthoquinones. These structures are as well an interesting scaffold for further synthetic transformations. The lack of reactivity in the DA reaction of the (*Z*) dienes, was explained by the energy values obtained from the rotational energy curves. Besides their use in DA reactions, the preparation of these new dienes opens new possibilities for further synthetic transformations, such as the synthesis of polymers, and also as substrates for additional transformations by organometallic chemistry.

## Experimental procedure

### General procedures

All solvents used for chromatography were distilled from glass. All NMR spectra were recorded on Bruker AC-200 (200.13 MHz), Fourier 300 (300 MHz) and Bruker Avance III (500.13 MHz) spectrometers, using the signal of residual non deuterated solvent as internal reference; *J* values are given in Hz. All 2D NMR experiments (COSY, DEPT-HSQC, HMBC) were performed using standard pulse sequences. ESI-HRMS spectra were recorded on a Bruker microTOF-Q II spectrometer. UV spectra were obtained on a Hewlett Packard 8453 spectrophotometer. TLC separations and analyses were carried out on Merck Silicagel 60 F254 plates. TLC plates were observed under UV light (254 nm) or sprayed with 2% vanillin in concentrated  $H_2SO_4$ . Merck Silica gel (230–400 mesh) was used for column chromatography. Sephadex LH-20 was obtained from GE Healthcare. All the reagents for synthesis were purchased from Sigma-Aldrich.

### Synthesis of compounds 1a/b–7a/b

The indole or carbazole (1–7) was added to a solution of excess NaOH in DMSO (0.5 mL per 20 mg indole) in a reaction vial at



room temperature. The reaction mixture was stirred for 10 minutes at 70 °C, after which 2.0 equivalents of 1-Br-4-butyne were added. The temperature was kept at 70 °C until total disappearance (by TLC) of the starting material, and a darkening of the reaction medium. The crude reaction mixture was then partitioned between EtOAc and brine, and the organic phase was washed twice again with brine, and finally with distilled water. The organic layer was then taken to dryness, and the 1 : 1 mixture of (*E*) and (*Z*) dienes (by NMR inspection) was obtained without further purification. In all cases, the yields were higher than 85–90%. The individual (*E*) and (*Z*) dienes were purified by preparative TLC on silica, using typically cyclohexane as mobile phase and characterized by 1D and 2D NMR and HRMS.

### Synthesis of compounds 1c–5c and 7c

Compounds 1a/b–5a/b or 7a/b were added to a solution of 2 eq. of *p*-benzoquinone in ethanol. The reaction mixture was kept at room temperature for 4 hs, after which the ethanol was evaporated. The solid residue was dissolved in MeOH, permeated through a Sephadex LH-20 column using MeOH as mobile phase, and finally purified by flash column chromatography using cyclohexane/EtOAc 9 : 1 as eluant.

### Compounds 1a–1b

45.6 mg as mixture, yield 95.0%. Oil.

**(*E*)-1-(Buta-1,3-dien-1-yl)-1*H*-indole (1a).** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 5.13 (d, *J* = 10, 1H, H<sub>4'a</sub>), 5.29 (d, *J* = 16.5, 1H, H<sub>4'b</sub>), 6.41 (dd, *J*<sub>1</sub> = 10.5, *J*<sub>2</sub> = 13.5, 1H, H<sub>2'</sub>), 6.53 (dt, *J*<sub>1</sub> = 16.5, *J*<sub>2</sub> = 10.5, 1H, H<sub>3'</sub>), 6.69 (d, *J* = 3.5, 1H, H<sub>3</sub>), 7.20 (dt, *J*<sub>1</sub> = 7.5, *J*<sub>2</sub> = 1, 1H, H<sub>6</sub>), 7.25 (d, *J* = 13.5, 1H, H<sub>1'</sub>), 7.30 (m, 1H, H<sub>6</sub>), 7.44 (d, *J* = 3.5, 1H, H<sub>2</sub>), 7.51 (dd, *J*<sub>1</sub> = 8, *J*<sub>2</sub> = 1, 1H, H<sub>7</sub>), 7.66 (dt, *J*<sub>1</sub> = 8, *J*<sub>2</sub> = 1, 1H, H<sub>4</sub>). <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>): 105.4 (C<sub>3</sub>), 109.5 (C<sub>7</sub>), 114.7 (C<sub>2'</sub>), 115.1 (C<sub>4'</sub>), 120.8 (C<sub>5</sub>), 121.2 (C<sub>4</sub>), 122.7 (C<sub>6</sub>), 123.5 (C<sub>2</sub>), 126.4 (C<sub>1'</sub>), 129.1 (C<sub>3a</sub>), 134.4 (C<sub>3'</sub>), 135.5 (C<sub>7a</sub>). HRESIMS calcd for [C<sub>12</sub>H<sub>12</sub>N]<sup>+</sup> (M + H) 170.0964, found 170.0555.

**(*Z*)-1-(Buta-1,3-dien-1-yl)-1*H*-indole (1b).** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 5.26 (d, *J* = 10, 1H, H<sub>4'a</sub>), 5.44 (d, *J* = 17, 1H, H<sub>4'b</sub>), 6.06 (dd, *J*<sub>1</sub> = 8.5, *J*<sub>2</sub> = 10.5, 1H, H<sub>2'</sub>), 6.66 (d, *J* = 3.5, 1H, H<sub>3</sub>), 6.76 (dt, *J*<sub>1</sub> = 17, *J*<sub>2</sub> = 10, 1H, H<sub>3'</sub>), 6.81 (d, *J* = 8.5, 1H, H<sub>1'</sub>), 7.20 (dt, *J*<sub>1</sub> = 7.5, *J*<sub>2</sub> = 1, 1H, H<sub>5</sub>), 7.28 (m, 1H, H<sub>6</sub>), 7.34 (d, *J* = 3.5, 1H, H<sub>2</sub>), 7.39 (dd, *J*<sub>1</sub> = 8, *J*<sub>2</sub> = 1, 1H, H<sub>7</sub>), 7.69 (dt, *J*<sub>1</sub> = 7.5, *J*<sub>2</sub> = 1, 1H, H<sub>4</sub>). <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>): 103.8 (C<sub>3</sub>), 110.1 (C<sub>7</sub>), 119.3 (C<sub>4'</sub>), 120.6 (C<sub>2'</sub>), 120.8 (C<sub>5</sub>), 120.9 (C<sub>4</sub>), 122.4 (C<sub>6</sub>), 123.5 (C<sub>1'</sub>), 127.9 (C<sub>2</sub>), 128.4 (C<sub>3a</sub>), 131.1 (C<sub>3'</sub>), 136.6 (C<sub>7a</sub>). HRESIMS calcd for [C<sub>12</sub>H<sub>12</sub>N]<sup>+</sup> (M + H) 170.0964, found 170.0555.

### Compounds 2a–2b

29.8 mg as mixture, yield 96.9%. Oil.

**(*E*)-1-(Buta-1,3-dien-1-yl)-5-bromo-1*H*-indole (2a).** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 5.13 (dd, *J*<sub>1</sub> = 10, *J*<sub>2</sub> = 1, 1H, H<sub>4'a</sub>), 5.29 (d, *J* = 16.5, *J* = 1, 1H, H<sub>4'b</sub>), 6.38 (dd, *J*<sub>1</sub> = 10.5, *J*<sub>2</sub> = 14, 1H, H<sub>2'</sub>), 6.54 (d, *J* = 3.5, 1H, H<sub>3</sub>), 6.48 (dt, *J*<sub>1</sub> = 16.5, *J*<sub>2</sub> = 10.5, 1H, H<sub>3'</sub>), 7.14 (d, *J* = 14, 1H, H<sub>1'</sub>), 7.20 (d, *J* = 8.5, 1H, H<sub>7</sub>), 7.28 (d, *J* = 3.5, 1H, H<sub>2</sub>), 7.33 (m, 1H, H<sub>6</sub>), 7.75 (dd, *J*<sub>1</sub> = 2, *J*<sub>2</sub> = 1, 1H, H<sub>4</sub>). <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>): δ 103.2 (C<sub>3</sub>), 111.7 (C<sub>7</sub>), 114.1 (C<sub>5</sub>), 115.7 (C<sub>2'</sub>),

116.0 (C<sub>4'</sub>), 123.4 (C<sub>4</sub>), 125.6 (C<sub>6</sub>), 126.0 (C<sub>1'</sub>), 129.1 (C<sub>2</sub>), 130.0 (C<sub>3a</sub>), 134.0 (C<sub>3'</sub>), 135.0 (C<sub>7a</sub>). HRESIMS calcd for [C<sub>12</sub>H<sub>11</sub>BrN]<sup>+</sup> (M + H) 248.0069, found 248.0059.

**(*Z*)-1-(Buta-1,3-dien-1-yl)-5-bromo-1*H*-indole (2b).** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 5.25 (d, *J* = 10, 1H, H<sub>4'a</sub>), 5.43 (d, *J* = 16.5, 1H, H<sub>4'b</sub>), 6.05 (dd, *J*<sub>1</sub> = 8.5, *J*<sub>2</sub> = 11, 1H, H<sub>2'</sub>), 6.57 (d, *J* = 3.5, 1H, H<sub>3</sub>), 6.63 (dt, *J*<sub>1</sub> = 16.5, *J*<sub>2</sub> = 10.5, 1H, H<sub>3'</sub>), 6.72 (d, *J* = 8.5, 1H, H<sub>1'</sub>), 7.32 (d, *J* = 8.5, 1H, H<sub>6</sub>), 7.34 (m, 1H, H<sub>7</sub>), 7.40 (d, *J* = 3.5, 1H, H<sub>2</sub>), 7.73 (dd, *J*<sub>1</sub> = 2, *J*<sub>2</sub> = 1, 1H, H<sub>4</sub>). <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>): δ 104.7 (C<sub>3</sub>), 110.9 (C<sub>7</sub>), 114.0 (C<sub>5</sub>), 120.1 (C<sub>4'</sub>), 122.0 (C<sub>2'</sub>), 123.1 (C<sub>1'</sub>), 123.7 (C<sub>4</sub>), 124.7 (C<sub>2</sub>), 125.2 (C<sub>6</sub>), 130.7 (C<sub>3'</sub>), 130.8 (C<sub>3a</sub>), 134.1 (C<sub>7a</sub>). HRESIMS calcd for [C<sub>12</sub>H<sub>11</sub>BrN]<sup>+</sup> (M + H) 248.0069, found 248.0059.

### Compounds 3a–3b

27.4 mg as mixture, yield 96.8%. Oil.

**(*E*)-1-(Buta-1,3-dien-1-yl)-5-chloro-1*H*-indole (3a).** NMR (500 MHz, CDCl<sub>3</sub>): δ 5.14 (dd, *J* = 10, H<sub>4'a</sub>), 5.29 (d, *J* = 16, 1H, H<sub>4'b</sub>), 6.37 (dd, *J*<sub>1</sub> = 10, *J*<sub>2</sub> = 13.5, 1H, H<sub>2'</sub>), 6.47 (dt, *J* = 10, *J* = 16, 1H, H<sub>3'</sub>), 6.61 (d, *J* = 3.5, 1H, H<sub>3</sub>), 7.15 (d, *J* = 13.5, 1H, H<sub>1'</sub>), 7.22 (dd, *J*<sub>1</sub> = 2, *J*<sub>2</sub> = 8.5, 1H, C<sub>6</sub>) 7.38 (d, *J* = 8.5, 1H, H<sub>7</sub>), 7.43 (d, *J* = 3.5, 1H, H<sub>2</sub>), 7.58 (d, *J* = 2, 1H, H<sub>7</sub>). <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>): δ 104.8 (C<sub>3</sub>), 110.5 (C<sub>7</sub>), 115.6 (C<sub>2'</sub>), 115.9 (C<sub>4'</sub>), 120.6 (C<sub>4</sub>), 122.7 (C<sub>6</sub>), 124.9 (C<sub>2</sub>), 126.1 (C<sub>1'</sub>), 126.3 (C<sub>3a</sub>), 130.1 (C<sub>5</sub>), 133.9 (C<sub>7a</sub>), 134.0 (C<sub>3'</sub>). HRESIMS calcd for [C<sub>12</sub>H<sub>11</sub>ClN]<sup>+</sup> (M + H) 204.0575, found 204.0585.

**(*Z*)-1-(Buta-1,3-dien-1-yl)-5-chloro-1*H*-indole (3b).** NMR (500 MHz, CDCl<sub>3</sub>): δ 5.26 (d, *J* = 10, 1H, H<sub>4'a</sub>), 5.43 (d, *J* = 16, 1H, H<sub>4'b</sub>), 6.05 (dd, *J*<sub>1</sub> = 8.5, *J*<sub>2</sub> = 11, 1H, H<sub>2'</sub>), 6.56 (d, *J* = 3.5, 1H, H<sub>3</sub>), 6.66 (dt, *J*<sub>1</sub> = 16, *J*<sub>2</sub> = 10, 1H, H<sub>3'</sub>), 6.73 (d, *J* = 8.5, 1H, H<sub>1'</sub>), 7.21 (dd, *J* = 8.5, *J* = 2, 1H, H<sub>6</sub>), 7.30 (d, *J* = 3.5, 1H, H<sub>2</sub>), 7.38 (d, *J* = 8.5, 1H, H<sub>7</sub>), 7.60 (d, *J* = 2, 1H, C<sub>4</sub>). <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>): δ 103.3 (C<sub>3</sub>), 110.5 (C<sub>7</sub>), 120.0 (C<sub>4'</sub>), 120.3 (C<sub>4</sub>), 121.9 (C<sub>2'</sub>), 122.7 (C<sub>6</sub>), 123.1 (C<sub>1'</sub>), 126.5 (C<sub>3a</sub>), 129.2 (C<sub>2</sub>), 129.4 (C<sub>5</sub>), 130.8 (C<sub>3'</sub>), 134.7 (C<sub>7a</sub>). HRESIMS calcd for [C<sub>12</sub>H<sub>11</sub>ClN]<sup>+</sup> (M + H) 204.0575, found 204.0585.

### Compounds 4a–4b

27.2 mg as mixture, yield 97.0%. Oil.

**(*Z*)-1-(Buta-1,3-dien-1-yl)-5-fluoro-1*H*-indole (4a).** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 5.24 (d, *J* = 10, 1H, H<sub>4'a</sub>), 5.43 (d, *J* = 17, 1H, H<sub>4'b</sub>), 6.05 (dd, *J*<sub>1</sub> = 8.5, *J*<sub>2</sub> = 10, 1H, H<sub>2'</sub>), 6.58 (d, *J* = 3.5, 1H, H<sub>3</sub>), 6.67 (dt, *J*<sub>1</sub> = 17, *J*<sub>2</sub> = 10, 1H, H<sub>3'</sub>), 6.74 (d, *J* = 8.5, 1H, H<sub>1'</sub>), 6.99 (td, *J*<sub>1</sub> = 2.5, *J*<sub>2</sub> = 9, H<sub>6</sub>), 7.25 (m, 1H, H<sub>4</sub>), 7.25 (m, 1H, H<sub>7</sub>), 7.32 (d, *J* = 3.5, 1H, H<sub>2</sub>). <sup>13</sup>C-NMR (500 MHz, CDCl<sub>3</sub>): δ 103.6 (d, *J* = 5, C<sub>3</sub>), 105.6 (d, *J* = 25, C<sub>4</sub>), 110.8 (d, *J* = 25, C<sub>7</sub>), 110.9 (d, *J* = 10, C<sub>6</sub>), 119.8, (C<sub>4'</sub>), 121.1 (C<sub>2'</sub>), 123.3 (C<sub>1'</sub>), 128.7 (d, *J* = 10, C<sub>3a</sub>), 129.5 (C<sub>2</sub>), 130.9 (C<sub>3'</sub>), 132.9 (C<sub>7a</sub>), 158.5 (d, *J* = 235, C<sub>5</sub>). HRESIMS calcd for [C<sub>12</sub>H<sub>11</sub>FN]<sup>+</sup> (M + H) 188.0870 found 188.0868.

**(*E*)-1-(Buta-1,3-dien-1-yl)-5-fluoro-1*H*-indole (4b).** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 5.10 (d, *J* = 10, H<sub>4'a</sub>), 5.28 (d, *J* = 17, 1H, H<sub>4'b</sub>), 6.38 (dd, *J*<sub>1</sub> = 10, *J*<sub>2</sub> = 13.5, 1H, H<sub>2'</sub>), 6.48 (dt, *J* = 10, *J* = 17, 1H, H<sub>3'</sub>), 6.60 (d, *J* = 3.5, 1H, H<sub>3</sub>), 7.00 (td, *J*<sub>1</sub> = 9, *J*<sub>2</sub> = 2.5, H<sub>6</sub>) 7.15 (d, *J* = 13.5, 1H, H<sub>1'</sub>), 7.25 (m, 1H, C<sub>4</sub>) 7.38 (dd, *J*<sub>1</sub> = 2.5, *J*<sub>2</sub> = 9, 1H, H<sub>4</sub>), 7.44 (d, *J* = 3.5, 1H, H<sub>2</sub>). <sup>13</sup>C-NMR (500 MHz, CDCl<sub>3</sub>): δ 105.2 (d, *J* = 5), 106.2 (d, *J* = 25), 110.2 (d, *J* = 10), 111.0 (d, *J* =



25), 115.5, 115.7, 125.1, 126.4, 129.5 (d,  $J = 10$ ), 132.0, 134.1, 158.4 (d,  $J = 235$ ). HRESIMS calcd for  $[C_{12}H_{11}FN]^+$  (M + H) 188.0870 found 188.0868.

### Compounds 5a–5b

26.8 mg as mixture, yield 96.5%. Oil.

**(Z)-1-(Buta-1,3-dien-1-yl)-6-fluoro-1H-indole (5a).**  $^1H$  NMR (500 MHz,  $CDCl_3$ ):  $\delta$  5.24 (d,  $J = 10.5$ ,  $H_{4'a}$ ), 5.43 (d,  $J = 17$ ,  $H_{4'b}$ ), 6.04 (dd,  $J_1 = 8.5$ ,  $J_2 = 10$ ,  $H_2$ ), 6.58 (d,  $J = 3.5$ ,  $H_3$ ), 6.67 (dt,  $J_1 = 10$ ,  $J_2 = 17$ ,  $H_3'$ ), 6.68 (d,  $J = 8.5$ ,  $H_{1'}$ ), 6.92 (dd,  $J_1 = 2.5$ ,  $J_2 = 10$ ,  $H_7$ ), 7.02 (dd,  $J_1 = 2.5$ ,  $J_2 = 10$ ,  $H_6$ ), 7.26 (d,  $J = 3.5$ ,  $H_2$ ), 7.52 (dd,  $J_1 = 5$ ,  $J_2 = 10$ ,  $H_4$ ).  $^{13}C$  NMR (125 MHz,  $CDCl_3$ ):  $\delta$  96.8 (d,  $J = 25$ ,  $C_6$ ), 103.8 ( $C_3$ ), 109.2 (d,  $J = 25$ ,  $C_7$ ), 119.3 ( $C_{4'}$ ), 121.6 (d,  $J = 10$ ,  $C_4$ ), 121.7 ( $C_{2'}$ ), 123.2 ( $C_{1'}$ ), 124.8 ( $C_{3a}$ ), 128.4 ( $C_3$ ), 130.9 ( $C_3'$ ), 136.4 (d,  $J = 10$ ,  $C_{7a}$ ), 160.1 (d,  $J = 235$ ,  $C_6$ ). HRESIMS calcd for  $[C_{12}H_{11}FN]^+$  (M + H) 188.0870 found 188.0868.

**(E)-1-(Buta-1,3-dien-1-yl)-6-fluoro-1H-indole (5b).**  $^1H$  NMR (500 MHz,  $CDCl_3$ ):  $\delta$  5.11 (d,  $J = 10$ , 1H,  $H_{4'a}$ ), 5.26 (d,  $J = 17$ , 1H,  $H_{4'b}$ ), 6.35 (dd,  $J_1 = 10.5$ ,  $J_2 = 13.5$ , 1H,  $H_2$ ), 6.46 (dt,  $J_1 = 10.5$ ,  $J_2 = 17$ , 1H,  $H_3'$ ), 6.59 (d,  $J = 3.5$ , 1H,  $H_3$ ), 6.90 (dd,  $J_1 = 2.5$ ,  $J_2 = 8.5$ , 1H,  $H_5$ ), 7.08 (d,  $J = 13.5$ , 1H,  $H_{1'}$ ), 7.12 (dd,  $J_1 = 2.5$ ,  $J_2 = 8.5$ , 1H,  $H_7$ ), 7.35 (d,  $J = 3.5$ , 1H,  $H_3$ ), 7.50 (dd,  $J_1 = 5$ ,  $J_2 = 8.5$ , 1H,  $H_7$ ).  $^{13}C$  NMR (125 MHz,  $CDCl_3$ ):  $\delta$  96.5 (d,  $J = 25$ ,  $C_7$ ), 105.3 ( $C_3$ ), 109.5 (d,  $J = 25$ ,  $C_5$ ), 115.4 ( $C_{2'}$ ), 115.8 ( $C_{4'}$ ), 121.9 (d,  $J = 10$ ,  $C_4$ ), 124.1 ( $C_2$ ), 126.1 ( $C_{1'}$ ), 128.4 ( $C_{3a}$ ), 134.0 ( $C_3'$ ), 135.5 (d,  $J = 10$ ,  $C_{7a}$ ), 160.2 (d,  $J = 235$ ,  $C_6$ ). HRESIMS calcd for  $[C_{12}H_{11}FN]^+$  (M + H) 188.0870 found 188.0868.

### Compounds 6a–6b

26.8 mg as mixture, yield 96.5%. Oil.

**(E)-5-(Benzyloxy)-1-(buta-1,3-dien-1-yl)-1H-indole (6a).**  $^1H$  NMR (500 MHz,  $CDCl_3$ ):  $\delta$  5.09 (d,  $J = 10$ ,  $H_1$ ); 7.12 (s,  $H_{1''}$ ); 5.25 (d,  $J = 16.5$ ,  $H_4'$ ); 6.36 (dd,  $J_1 = 13.5$ ,  $J_2 = 10$ ,  $H_2$ ); 6.48 (dt,  $J_1 = 10$ ,  $J_2 = 16.5$ ,  $H_3'$ ); 6.56 (d,  $J = 3$ ,  $H_3$ ); 7.00 (dd,  $J_1 = 6.5$ ,  $J_2 = 2.5$ ,  $H_6$ ); 7.15 (d,  $J = 13.5$ ,  $H_{1'}$ ); 7.16 (d,  $J = 2.5$ ,  $H_4$ ); 7.33 (t,  $J = 7.5$ ,  $H_5''$ ); 7.37 (d,  $J = 13.5$ ,  $H_7$ ); 7.37 (d,  $J = 3.0$ ,  $H_2$ ); 7.40 (t,  $J = 7.5$ ,  $H_4''$ ); 7.49 (d,  $J = 7.5$ ,  $H_3''$ ).  $^{13}C$ -NMR (500 MHz,  $CDCl_3$ ): d 70.8 ( $C_{1''}$ ); 104.7 ( $C_4$ ); 105.1 ( $C_3$ ); 110.3 ( $C_7$ ); 113.1 ( $C_6$ ); 114.4 ( $C_2$ ); 114.9 ( $C_{4'}$ ); 124.2 ( $C_2$ ); 126.7 ( $C_{1'}$ ); 127.5 ( $C_{3''}$ ); 127.8 ( $C_{5''}$ ); 128.5 ( $C_{4''}$ ); 129.6 ( $C_{3a}$ ); 130.8 ( $C_{7a}$ ); 134.4 ( $C_3'$ ); 137.4 ( $C_{2''}$ ); 154.0 ( $C_5$ ). HRESIMS calcd for  $[C_{19}H_{18}NO]^+$  (M + H) 276.1383 found 276.1395.

**(Z)-5-(Benzyloxy)-1-(buta-1,3-dien-1-yl)-1H-indole (6b).**  $^1H$  NMR (500 MHz,  $CDCl_3$ ):  $\delta$  5.12 (s,  $H_{1''}$ ); 5.23 (d,  $J = 10$ ,  $H_{4'}$ ); 5.40 (d,  $J = 16.5$ ,  $H_4$ ); 5.97 (dd,  $J_1 = 8.5$ ,  $J_2 = 11$ ,  $H_2$ ); 6.54 (d,  $J = 3.0$ ,  $H_3$ ); 6.73 (dt,  $J_1 = 16.5$ ,  $J_2 = 11$ ,  $H_3'$ ); 6.75 (d,  $J = 8.5$ ,  $H_{1'}$ ); 7.00 (dd,  $J_1 = 6.5$ ,  $J_2 = 2.5$ ,  $H_6$ ); 7.18 (d,  $J = 2.5$ ,  $H_4$ ); 7.26 (d,  $J = 9$ ,  $H_7$ ); 7.30 (d,  $J = 3.0$ ,  $H_2$ ); 7.33 (t,  $J = 7.5$ ,  $H_5''$ ); 7.40 (t,  $J = 7.5$ ,  $H_3''$ ); 7.49 (d,  $J = 7.5$ ,  $H_3''$ ).  $^{13}C$ -NMR (500 MHz,  $CDCl_3$ ):  $\delta$  70.8 ( $C_{1''}$ ); 103.6 ( $C_3$ ); 104.4 ( $C_4$ ); 110.9 ( $C_7$ ); 113.3 ( $C_6$ ); 119.1 ( $C_{4'}$ ); 120.2 ( $C_{2'}$ ); 123.5 ( $C_3'$ ); 127.5 ( $C_{3''}$ ); 127.8 ( $C_{5''}$ ); 128.5 ( $C_{4''}$ ); 128.5 ( $C_2$ ); 128.8 ( $C_{3a}$ ); 131.2 ( $C_{1'}$ ); 131.7 ( $C_{7a}$ ); 137.4 ( $C_{2''}$ ); 154.0 ( $C_5$ ).

### Compounds 7a–7b

22.1 mg as mixture, yield 86.2%. Oil.

**(E)-9(Buta-1,3-dien-1-yl)-9H-carbazole (7a).**  $^1H$  NMR (500 MHz,  $CDCl_3$ ):  $\delta$  5.18 (d,  $J = 10$ , 1H,  $H_{4'}$ ), 5.36 (d,  $J = 17$ , 1H,  $H_{4'}$ ), 6.60 (dt,  $J_1 = 10$ ,  $J_2 = 17$ , 1H,  $H_3'$ ), 6.76 (dd,  $J_1 = 10$ ,  $J_2 = 13.5$ , 1H,  $H_2$ ), 7.31 (m, 1H,  $H_{1'}$ ), 7.31 (m, 2H,  $H_3$ ), 7.48 (t,  $J = 8, 2H$ ,  $H_2$ ), 7.66 (d,  $J = 8, 2H$ ,  $H_1$ ), 8.09 (d,  $J = 8, 2H$ ,  $H_4$ ).  $^{13}C$  NMR (125 MHz,  $CDCl_3$ ):  $\delta$  110.5 ( $C_1$ ), 115.8 ( $C_{4'}$ ), 119.9 ( $C_2$ ), 120.1 ( $C_4$ ), 120.8 ( $C_3$ ), 120.8 ( $C_{1'}$ ), 124.2 ( $C_{4a}$ ), 126.3 ( $C_2$ ), 134.8 ( $C_3'$ ), 139.3 ( $C_{9a}$ ). HRESIMS calcd for  $[C_{16}H_{14}N]^+$  (M + H) 220.1121 found 220.1115.

**(Z)-9(Buta-1,3-dien-1-yl)-9H-carbazole (7b).**  $^1H$  NMR (500 MHz,  $CDCl_3$ ):  $\delta$  5.20 (d,  $J = 9$ ,  $H_{4'a}$ ), 5.44 (d,  $J = 17$ ,  $H_{4'b}$ ), 6.37 (m,  $H_3'$ ), 6.38 (m,  $H_2'$ ), 6.72 (d,  $J = 8.5$ ,  $H_{1'}$ ), 7.29 (t,  $J = 8$ , 2H,  $H_3$ ), 7.36 (d,  $J = 8$ , 2H,  $H_1$ ), 7.46 (t,  $J = 8$ , 2H,  $H_2$ ), 8.09 (d,  $J = 8$ , 2H,  $H_4$ ).  $^{13}C$  NMR (125 MHz,  $CDCl_3$ ):  $\delta$  110.5 ( $C_1$ ), 119.6 ( $C_{4'}$ ), 120.1 ( $C_4$ ), 120.2 ( $C_3$ ), 122.7 ( $C_{1'}$ ), 123.6 ( $C_{4a}$ ), 126.0 ( $C_2$ ), 127.3 ( $C_{2'}$ ), 132.0 ( $C_3'$ ), 140.4 ( $C_{9a}$ ). HRESIMS calcd for  $[C_{16}H_{14}N]^+$  (M + H) 220.1121 found 220.1115.

**5-(1H-Indol-1-yl)naphthalene-1,4-dione (1c).**  $^1H$  NMR (500 MHz,  $CDCl_3$ ):  $\delta$  6.75 (d,  $J = 3.5$ , 1H,  $C_3'$ ), 6.82 (d,  $J = 10$ , 1H,  $H_3$ ), 6.98 (d,  $J = 10$ , 1H,  $H_2$ ), 7.00 (d,  $J = 8$ , 1H,  $H_7$ ), 7.12 (d,  $J = 3.5$ , 1H,  $H_2$ ), 7.16 (t,  $J = 8$ , 1H,  $H_5'$ ), 7.18 (t,  $J = 8$ , 1H,  $H_6'$ ), 7.71 (d,  $J = 8$ , 1H,  $H_4'$ ), 7.79 (d,  $J = 8$ , 1H,  $H_6$ ), 7.88 (t,  $J = 8$ , 1H,  $H_7$ ), 8.26 (d,  $J = 8$ , 1H,  $H_8$ ).  $^{13}C$  NMR (125 MHz,  $CDCl_3$ ):  $\delta$  104.0 ( $C_3'$ ), 109.8 ( $C_7$ ), 120.5 ( $C_6'$ ), 121.3 ( $C_{4'}$ ), 122.4 ( $C_5'$ ), 126.7 ( $C_{8a}$ ), 126.8 ( $C_8$ ), 128.5 ( $C_{2'}$ ), 129.0 ( $C_{3a'}$ ), 134.1 ( $C_{4a}$ ), 134.3 ( $C_7$ ), 135.4 ( $C_6$ ), 136.5 ( $C_{7a'}$ ), 136.8 ( $C_2$ ), 138.5 ( $C_5$ ), 140.3 ( $C_3$ ), 183.0 ( $C_4$ ), 184.3 ( $C_1$ ). HRESIMS calcd for  $[C_{18}H_{12}N]^+$  (M + H) 274.0863 found 274.0860.

**5-(5-Bromo-1H-indol-1-yl)naphthalene-1,4-dione (2c).**  $^1H$  NMR (500 MHz,  $CDCl_3$ ):  $\delta$  6.70 (d,  $J = 3.5$ , 1H,  $H_3'$ ), 6.83 (d,  $J = 10$ , 1H,  $H_2$ ), 6.86 (d,  $J = 9$ , 1H,  $H_7$ ), 6.99 (d,  $J = 10$ , 1H,  $H_3$ ), 7.09 (d,  $J = 3.5$ , 1H,  $H_2$ ), 7.22 (dd,  $J_1 = 9$  Hz,  $J_2 = 2$ , 1H,  $H_6'$ ), 7.76 (d,  $J = 8$ , 1H,  $H_6$ ), 7.84 (d,  $J = 2$ , 1H,  $H_4$ ), 7.90 (t,  $J = 8$ , 1H,  $H_7$ ), 8.29 (d,  $J = 8$ , 1H,  $H_8$ ).  $^{13}C$  NMR (125 MHz,  $CDCl_3$ ):  $\delta$  103.4 ( $C_3'$ ), 111.3 ( $C_7$ ), 113.7 ( $C_5'$ ), 123.8 ( $C_{4'}$ ), 125.3 ( $C_6'$ ), 126.8 ( $C_{8a}$ ), 127.2 ( $C_8$ ), 128.8 ( $C_{2'}$ ), 130.6 ( $C_{3a'}$ ), 134.1 ( $C_{4a}$ ), 134.4 ( $C_7$ ), 135.3 ( $C_6$ ), 135.4 ( $C_{7a'}$ ), 137.0 ( $C_3$ ), 137.9 ( $C_5$ ), 140.2 ( $C_2$ ), 183.1 ( $C_4$ ), 184.2 ( $C_1$ ). HRESIMS calcd for  $[C_{18}H_{11}BrN]^+$  (M + H) 351.9968 found 351.9957.

**5-(5-Chloro-1H-indol-1-yl)naphthalene-1,4-dione (3c).**  $^1H$  NMR (500 MHz,  $CDCl_3$ ):  $\delta$  6.69 (d,  $J = 3.5$ , 1H,  $H_3'$ ), 6.82 (d,  $J = 10$ , 1H,  $H_2$ ), 6.90 (d,  $J = 9$ , 1H,  $H_7$ ), 6.98 (d,  $J = 10$ , 1H,  $H_3$ ), 7.09 (dd,  $J_1 = 9$  Hz,  $J_2 = 2$ , 1H,  $H_6'$ ), 7.14 (d,  $J = 3.5$ , 1H,  $H_2$ ), 7.68 (d,  $J = 2$ , 1H,  $H_4$ ), 7.73 (d,  $J = 8$ , 1H,  $H_6$ ), 7.90 (t,  $J = 8$ , 1H,  $H_7$ ), 8.28 (d,  $J = 8$ , 1H,  $H_8$ ).  $^{13}C$  NMR (125 MHz,  $CDCl_3$ ):  $\delta$  103.5 ( $C_3'$ ), 110.8 ( $C_7$ ), 120.7 ( $C_{4'}$ ), 122.7 ( $C_6'$ ), 126.1 ( $C_5'$ ), 126.8 ( $C_{8a}$ ), 127.2 ( $C_8$ ), 129.8 ( $C_{2'}$ ), 130.0 ( $C_{7a'}$ ), 134.1 ( $C_{4a}$ ), 134.4 ( $C_7$ ), 135.1 ( $C_6$ ), 135.3 ( $C_{3a'}$ ), 137.0 ( $C_2$ ), 137.9 ( $C_5$ ), 140.2 ( $C_3$ ), 183.0 ( $C_4$ ), 184.2 ( $C_1$ ). HRESIMS calcd for  $[C_{18}H_{11}ClN]^+$  (M + H) 308.0473 found 308.0859.

**5-(5-Fluoro-1H-indol-1-yl)naphthalene-1,4-dione (4c).**  $^1H$  NMR (500 MHz,  $CDCl_3$ ):  $\delta$  6.71 (d,  $J = 3.5$ , 1H,  $C_3'$ ), 6.82 (d,  $J = 10.5$ , 1H,  $H_3$ ), 6.89 (m, 1H,  $H_7$ ), 6.92 (m, 1H,  $H_6'$ ), 6.98 (d,  $J = 10.5$ , 1H,  $H_2$ ), 7.15 (d,  $J = 3.5$ , 1H,  $H_2$ ), 7.35 (dd,  $J_1 = 9$ ,  $J_2 = 2.5$ , 1H,  $H_4'$ ), 7.78 (d,  $J = 8$ , 1H,  $H_6$ ), 7.89 (t,  $J = 8$ , 1H,  $H_7$ ), 8.27 (d,  $J = 8$ , 1H,  $H_8$ ).  $^{13}C$  NMR (125 MHz,  $CDCl_3$ ):  $\delta$  103.9 ( $C_3'$ ), 106.1 (d,  $J_{CF}$





= 25 Hz, C<sub>4'</sub>), 110.5 (d, J<sub>CF</sub> = 10 Hz, C<sub>7'</sub>), 110.7 (d, J<sub>CF</sub> = 25 Hz, C<sub>6'</sub>), 126.7 (C<sub>8a</sub>), 127.0 (C<sub>8</sub>), 129.5 (d, J<sub>CF</sub> = 10 Hz, C<sub>3a</sub>), 130.0 (C<sub>2'</sub>), 133.2 (C<sub>7a'</sub>), 134.1 (C<sub>4a</sub>), 134.4 (C<sub>7</sub>), 135.4 (C<sub>6</sub>), 136.9 (C<sub>2</sub>), 138.2 (C<sub>5</sub>), 140.2 (C<sub>3</sub>), 158.5 (d, J<sub>CF</sub> = 235 Hz, C<sub>5'</sub>), 182.9 (C<sub>4</sub>), 184.4 (C<sub>1</sub>). HRESIMS calcd for [C<sub>18</sub>H<sub>11</sub>FN]<sup>+</sup> (M + H) 292.0768 found 292.0783.

**5-(6-Fluoro-1H-indol-1-yl)naphthalene-1,4-dione (5c).** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 6.67 (dd, J<sub>1</sub> = 10 Hz, J<sub>2</sub> = 2.5, 1H, H<sub>7'</sub>), 6.73 (d, J = 3.5, 1H, H<sub>3'</sub>), 6.83 (d, J = 10.5, 1H, H<sub>2</sub>), 6.92 (td, J<sub>1</sub> = 8.5, J<sub>2</sub> = 2.5, 1H, H<sub>5'</sub>), 6.99 (d, J = 10.5, 1H, H<sub>3</sub>), 7.09 (d, J = 3.5, 1H, H<sub>2</sub>), 7.61 (dd, J<sub>1</sub> = 8.5, J<sub>2</sub> = 5, 1H, H<sub>4'</sub>), 7.77 (d, J = 8, 1H, H<sub>6</sub>), 7.90 (t, J = 8, 1H, H<sub>7</sub>), 8.29 (d, J = 8, 1H, H<sub>8</sub>). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 96.5 (d, J<sub>CF</sub> = 25 Hz, C<sub>7'</sub>), 104.2 (C<sub>3</sub>), 109.1 (d, J<sub>CF</sub> = 25 Hz, C<sub>5'</sub>), 121.5 (d, J<sub>CF</sub> = 10 Hz, C<sub>4'</sub>), 125.3 (C<sub>3a'</sub>), 126.7 (C<sub>8a</sub>), 127.2 (C<sub>8</sub>), 128.8 (C<sub>2'</sub>), 134.1 (C<sub>4a</sub>), 134.4 (C<sub>7</sub>), 135.2 (C<sub>6</sub>), 136.7 (d, J<sub>CF</sub> = 10 Hz, C<sub>7a'</sub>), 136.9 (C<sub>3</sub>), 138.0 (C<sub>5</sub>), 140.2 (C<sub>2</sub>), 160.2 (d, J<sub>CF</sub> = 235 Hz, C<sub>6'</sub>), 182.5 (C<sub>4</sub>), 184.3 (C<sub>1</sub>). HRESIMS calcd for [C<sub>18</sub>H<sub>11</sub>FN]<sup>+</sup> (M + H) 292.0768 found 292.0762.

**5-(9H-Carbazol-9-yl)naphthalene-1,4-dione (7c).** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 6.73 (d, J = 10.5, 1H, H<sub>3</sub>), 6.96 (d, J = 10.5, 1H, H<sub>2</sub>), 6.97 (d, J = 8, 2H, H<sub>2'</sub>), 7.28 (t, J = 8, 2H, H<sub>4</sub>), 7.34 (t, J = 8, 2H, H<sub>3'</sub>), 7.88 (d, J = 8, 1H, H<sub>6</sub>), 7.98 (t, J = 8, 1H, H<sub>7</sub>), 8.17 (d, J = 8, 2H, H<sub>5'</sub>), 8.36 (d, J = 8, 1H, H<sub>8</sub>). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 109.2 (C<sub>2'</sub>), 120.2 (C<sub>4'</sub>), 120.6 (C<sub>5'</sub>), 123.8 (C<sub>5a'</sub>), 125.9 (C<sub>3'</sub>), 127.4 (C<sub>8</sub>), 128.0 (C<sub>8a</sub>), 134.5 (C<sub>4a</sub>), 134.9 (C<sub>7</sub>), 136.5 (C<sub>5</sub>), 136.8 (C<sub>2</sub>), 137.1 (C<sub>6</sub>), 140.2 (C<sub>3</sub>), 140.9 (C<sub>1a'</sub>), 182.8 (C<sub>1</sub>), 184.5 (C<sub>4</sub>). HRESIMS calcd for [C<sub>22</sub>H<sub>14</sub>NO<sub>2</sub>]<sup>+</sup> (M + H) 324.1019 found 324.1031.

### Isolation of compound 12a

When the basic catalyzed isomerization of indole (**1**) was quenched after 45 minutes, compound **12a** could be isolated by preparative TLC using cyclohexane/ethyl acetate (9 : 1) as mobile phase and characterized by 1D and 2D NMR and HRMS.

**1-(But-2-yn-1-yl)-1H-indole (12a).** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 1.83 (t, J = 2.5, 3H, H<sub>4</sub>), 4.83 (t, J = 2.5, 2H, H<sub>1</sub>), 6.51 (d, J = 3, 1H, H<sub>3</sub>), 7.12 (t, J = 8, 1H, H<sub>5</sub>), 7.23 (d, J = 3, 1H, H<sub>2</sub>), 7.24 (t, J = 8, 1H, H<sub>6</sub>), 7.40 (d, J = 8, 1H, H<sub>7</sub>), 7.63 (d, J = 8, 1H, H<sub>4</sub>). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 3.56 (C<sub>4'</sub>), 36.3 (C<sub>1'</sub>), 73.2 (C<sub>2'</sub>), 81.3 (C<sub>3'</sub>), 101.4 (C<sub>3</sub>), 109.5 (C<sub>7</sub>), 119.6 (C<sub>5</sub>), 121.1 (C<sub>4</sub>), 121.7 (C<sub>6</sub>), 127.2 (C<sub>2</sub>), 128.8 (C<sub>4a</sub>), 135.7 (C<sub>7a</sub>). HRESIMS calcd for [C<sub>12</sub>H<sub>12</sub>N]<sup>+</sup> (M + H) 170.0964, found 170.0557.

### Cytotoxicity assays

Human leukemic K562 cells were obtained from ATCC, the murine mammary adenocarcinoma LM2 cells were provided by Dr A. Eijan (Instituto Roffo, Argentina), while the human normal keratinocytes HaCaT were obtained from Dr M. Quintanilla (Instituto de Investigaciones Biomedicas, Madrid, Spain). The cells were cultured in RPMI 1640 medium, supplemented with 5% fetal bovine serum (LM2) and 10% (K562 and HaCat), 2 mM L-glutamine, 100 IU mL<sup>-1</sup> penicillin, 100 µg mL<sup>-1</sup> streptomycin and maintained at 37 °C in a 5% CO<sub>2</sub> atmosphere. Cells were detached with 0.1% trypsin-EDTA, and viable cells were counted using a hemacytometer. Cells (70 000 to 10 000 cells per mL) were seeded in 48-well microtiter plates and incubated at

37 °C. After 24 h, the cells were treated with different concentrations (1–100 µM) of the test compounds initially dissolved in DMSO (5 mM), and further diluted in medium to produce the desired concentrations. Final DMSO concentrations were lower than 2%. The plates were incubated for another 48 h at 37 °C. Immediately after treatment, cell viability was measured employing the MTT method.<sup>22</sup> Briefly, 25 µL of MTT (2.5 mg mL<sup>-1</sup>) was added to the wells and incubated for 1 h. After DMSO dissolution of the resulting formazan crystals, absorbance was recorded at 570 nm in a microplate reader. The concentrations required to inhibit cell growth by 50% (IC<sub>50</sub>) were calculated from the abscissa intercept from logistic curves constructed by plotting cell survival (%) versus drug concentration (µM).

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

Research at the University of Buenos Aires was supported by grants from CONICET (PIP 2014–2016 No. 11220130100523CO), UBA (UBACyT 2014–2017 No. 20020130100457BA) and ANPCyT (PICT 2014–2063). We thank Dr Gabriela Cabrera (UMYMFOR-CONICET) for recording the mass spectra and Eng. José Gallardo and Lic. Gernot Eskuche (UMYMFOR-CONICET) for the NMR spectra. G. C., G. D. V., R. P. D. and J. A. P are researchers of CONICET. C. P. D. thanks CONICET for a doctoral fellowship, and J. F. thanks the University of Buenos Aires for an undergraduate research fellowship.

## Notes and references

- For recent examples of syntheses of substituted 1,3-butadienes, see: (a) V. Bandi, V. Kavala, C. H. Hsu, A. Konala, B. K. Villuri, T. Kotipalli, C. W. Kuo and C. F. Yao, *RSC Adv.*, 2017, 7, 46704–46712; (b) S. Zhou, E. Sánchez-Larios and M. Gravel, *J. Org. Chem.*, 2012, 77, 3576–3582; (c) L. Wang and M. E. Welker, *J. Org. Chem.*, 2012, 77, 8280–8286; (d) Q. Zhao, V. Tognetti, L. Joubert, T. Besset, X. Pannecouque, J. P. Bouillon and T. Poisson, *Org. Lett.*, 2017, 19, 2106–2109; (e) J. Sudkowska-Łęcka, B. Marciniec, G. Hreczycho, M. Kubicki and P. Pawluć, *Org. Lett.*, 2015, 17, 2366–2369; (f) J. Sudkowska-Łęcka, M. Taczala and P. Pawluć, *Materials*, 2015, 8, 7250–7256; (g) T. Liu, J. Dong, S. J. Cao, L. C. Guo and L. Wu, *RSC Adv.*, 2014, 4, 61722–617261; (h) X. M. Zhang, G. Q. Wu and W. Z. Chen, *Chin. J. Chem.*, 2007, 25, 1722–1727.
- N. Chadha and O. Silakari, *Eur. J. Med. Chem.*, 2017, 134, 159–184.
- (a) C. W. Kuo, A. Konala, L. Ling, T. T. Chiang, C. Y. Huang, T. H. Yang, V. Kavala and C. F. Yao, *Chem. Commun.*, 2016, 52, 7870–7873; (b) C. C. Nawrat and C. J. Moody, *Angew. Chem., Int. Ed.*, 2014, 53, 2056–2077.
- (a) P. Pawluć, A. Franczyk, J. Walkowiak, G. Hreczycho, M. Kubicki and B. Marciniec, *Org. Lett.*, 2011, 13, 1976–1979; (b) P. Pawluć, A. Franczyk, J. Walkowiak,





- G. Hreczycho, M. Kubicki and B. Marciniec, *Tetrahedron*, 2012, **68**, 3545–3551; (c) J. Sudkowska-Frątczak, A. Ryba, A. Franczyk, J. Walkowiak, M. Kubicki and P. Pawluć, *Appl. Organomet. Chem.*, 2014, **28**, 137–139.
- 5 H. Pines and W. Stalick, Base catalyzed reaction of hydrocarbons and related compounds, *Chapter 3: Isomerization of Acetylenes and Allenes*, Academic Press, New York, 1977, pp. 124–204.
- 6 W. Smadja, *C. R. Acad. Sci. Paris*, 1963, **257**, 3950–3952.
- 7 (a) A. J. Hubert and H. G. Viehe, *J. Chem. Soc. C*, 1968, 228–230; (b) A. J. Hubert and H. Reimlinger, *J. Chem. Soc. C*, 1968, 606–608.
- 8 (a) T. L. Jacobs, R. Akawie and R. G. Cooper, *J. Am. Chem. Soc.*, 1951, **73**, 1273–1276; (b) S. W. Benson, F. R. Cruickshank, D. M. Golden, G. R. Haugen, H. E. O'Neal, A. S. Rogers, R. Shaw and R. Walsh, *Chem. Rev.*, 1969, **69**, 279–324.
- 9 J. Dale, Properties of acetylenic compounds, in *Chemistry of Acetylenes*, ed. H. G. Viehe, Dekker, New York, 1969, p. 78; C. Bernasconi and P. Wenzel, *J. Am. Chem. Soc.*, 2001, **123**, 7146–7153.
- 10 F. Neese, *Wiley Interdiscip. Rev.: Comput. Mol. Sci.*, 2012, **2**, 73–78.
- 11 Y. Zhao and D. G. Truhlar, *Theor. Chem. Acc.*, 2008, **120**, 215–241.
- 12 F. Weigend and R. Ahlrichs, *Phys. Chem. Chem. Phys.*, 2005, **7**, 3297–3305.
- 13 F. Neese, F. Wennmohs, A. Hansen and U. Becker, *Chem. Phys.*, 2009, **356**, 98–109.
- 14 F. Weigend, *Phys. Chem. Chem. Phys.*, 2006, **8**, 1057–1065.
- 15 S. Sinnecker, A. Rajendran, A. Klamt, M. Diedenhofen and F. Neese, *J. Phys. Chem. A*, 2006, **110**, 2235–2245.
- 16 R. Huisgen, R. Grashey and J. Sauer, Cycloaddition Reactions of Alkenes, in *The chemistry of alkenes*, ed. S. Patai, ch. 11, Interscience Publishers, 1964, pp. 739–954.
- 17 (a) W. Roush and D. Barda, *J. Am. Chem. Soc.*, 1997, **119**, 7402–7403; (b) H. Adams, J. C. Anderson, R. Bell, D. N. Jones, M. R. Peel and N. C. O. Tomkinson, *J. Chem. Soc., Perkin Trans. 1*, 1998, 3967–3973; (c) N. Yakelis and W. Roush, *Org. Lett.*, 2001, **3**, 957–960.
- 18 H. Y. Qiu, P. F. Wang, H. Y. Lin, C. Y. Tang, H. L. Zhu and Y. H. Yang, *Chem. Biol. Drug Des.*, 2018, **91**, 681–690.
- 19 A. P. Dobbs, K. Jones and K. T. Veal, *Tetrahedron*, 1998, **54**, 2149–2160.
- 20 P. Kielkowski, H. Cahová, R. Pohl and M. Hocek, *Bioorg. Med. Chem.*, 2016, **24**, 1268–1276.
- 21 M. Čížková, D. Šaman, D. Koval, V. Kašička, B. Klepetářová, I. Císařová and F. Teplý, *Eur. J. Org. Chem.*, 2014, 5681–5685.
- 22 F. Denizot and R. Lang, *J. Immunol. Methods*, 1986, **89**, 271–277.

